- Oops!Something went wrong.Please try again later.
Company actively pursuing Collagen VI pathway identified in peer-reviewed publication
MENLO PARK, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that Lynn Williams, Ph.D., has been awarded the International Dupuytren Award 2021 for Basic Research.
Dr. Williams is a research fellow at the Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, University of Oxford, Oxford, England, whose research is being sponsored by 180 Life Sciences. Dr. Williams won the award for her paper published in a peer-reviewed journal in 2020. The paper titled "Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300," published in Proceedings of the National Academy of Science, USA, identified the collagen VI pathway that 180 Life Sciences is now actively pursuing in preclinical studies. The manuscript was published as a result of Dr. Williams’ work as a member of Professor Jagdeep Nanchahal’s research team. Professor Nanchahal serves as Chairman of 180 Life Sciences’ Clinical Advisory Board and is a recognized pioneer in the treatment of fibrosis of the hand.
Dr. James Woody, CEO of 180 Life Sciences commented, “This pivotal research for which Dr. Williams has received this award, was published in a high-impact journal and provides insight into Collagen VI pathways to identify novel potential therapeutic targets for fibrotic diseases. This research from our team, led by Professor Jagdeep Nanchahal, is the foundation of our program to develop new treatments for fibrosis.”
The International Dupuytren Society is a patient organization that brings together Dupuytren Disease patient societies worldwide. Dr. Thomas Layton, another member of Professor Nanchahal’s research team in Oxford was the joint recipient of the International Dupuytren Award in 2020 and in 2019 for his paper in Science Advances where the team identified TNFR2 and IL-33 as therapeutic targets in localized fibrotic diseases. Professor Jagdeep Nanchahal and his clinical research team were proud recipients of the Award in 2019 for their publication of the phase 2a clinical trial data published in Lancet EBiomedicine.
About 180 Life Sciences Corp.
180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The Company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The Company’s primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor), with its lead program in phase 2b clinical trial.
This press release includes "forward-looking statements", including information about management’s view of the Company’s future expectations, plans and prospects, within the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 (the “Act”). Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results and, consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements and factors that may cause such differences include, without limitation, statements relating to expectations regarding the capitalization, resources, and funding of the Company; expectations with respect to future performance, growth and anticipated acquisitions; the continued listing of the Company on The NASDAQ Stock Market; the ability of the Company to execute its plans to develop and market new drug products and the timing and costs of these development programs; estimates of the size of the markets for its potential drug products; potential litigation involving the Company or the validity or enforceability of the intellectual property of the Company; global economic conditions; geopolitical events and regulatory changes; the expectations, development plans and anticipated timelines for the Company's drug candidates, pipeline and programs, including collaborations with third parties; access to additional financing, and the potential lack of such financing; and the Company’s ability to raise funding in the future and the terms of such funding. These risk factors and others are included from time to time in documents the Company files with the Securities and Exchange Commission, including, but not limited to, its Form 10-Ks, Form 10-Qs and Form 8-Ks, as well as in the definitive proxy statement/prospectus that the Company filed in connection with the recent merger. These reports and filings are available at www.sec.gov. All subsequent written and oral forward-looking statements concerning the Company or other matters and attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, including the forward-looking statements included in this press release, which are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as otherwise provided by law.
Director of IR
180 Life Sciences Corp